Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

NDMA In Ranitidine Risks Rerun Of Sartans Crisis

Sep 16 2019

• By David Wallace

Nitrosodimethylamine — Canadian, European and US regulators are evaluating the discovery of NDMA in ranitidine • Source: Shutterstock

Related Content

FDA Lists Impurity-Free Valsartan And Other ARB Drugs

Apr 11 2019

Impure valsartan API prompts recalls in EU

Jul 13 2018

US FDA Scrutinizes Process Risks After Nitrosamines Found In ARBs

Aug 30 2019

EU Takes Action To Prevent Further Impurities After Sartans

May 07 2019

Additional Topics

Europe Canada United States Generic Drugs Regulation BioPharmaceutical

More from Generics

More from Products

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.